|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TXNDC9 |
Gene summary for TXNDC9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TXNDC9 | Gene ID | 10190 |
| Gene name | thioredoxin domain containing 9 | |
| Gene Alias | APACD | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O14530 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10190 | TXNDC9 | LZE4T | Human | Esophagus | ESCC | 3.32e-13 | 4.75e-01 | 0.0811 |
| 10190 | TXNDC9 | LZE7T | Human | Esophagus | ESCC | 1.41e-05 | 5.37e-01 | 0.0667 |
| 10190 | TXNDC9 | LZE8T | Human | Esophagus | ESCC | 3.64e-08 | 1.34e-01 | 0.067 |
| 10190 | TXNDC9 | LZE20T | Human | Esophagus | ESCC | 3.69e-04 | 1.61e-01 | 0.0662 |
| 10190 | TXNDC9 | LZE22T | Human | Esophagus | ESCC | 1.96e-04 | 3.05e-01 | 0.068 |
| 10190 | TXNDC9 | LZE24T | Human | Esophagus | ESCC | 8.24e-16 | 5.09e-01 | 0.0596 |
| 10190 | TXNDC9 | LZE21T | Human | Esophagus | ESCC | 3.69e-07 | 4.57e-01 | 0.0655 |
| 10190 | TXNDC9 | P2T-E | Human | Esophagus | ESCC | 6.75e-30 | 6.69e-01 | 0.1177 |
| 10190 | TXNDC9 | P4T-E | Human | Esophagus | ESCC | 1.52e-31 | 8.98e-01 | 0.1323 |
| 10190 | TXNDC9 | P5T-E | Human | Esophagus | ESCC | 2.16e-15 | 4.55e-01 | 0.1327 |
| 10190 | TXNDC9 | P8T-E | Human | Esophagus | ESCC | 6.68e-17 | 3.40e-01 | 0.0889 |
| 10190 | TXNDC9 | P9T-E | Human | Esophagus | ESCC | 5.28e-17 | 5.88e-01 | 0.1131 |
| 10190 | TXNDC9 | P10T-E | Human | Esophagus | ESCC | 2.40e-39 | 6.35e-01 | 0.116 |
| 10190 | TXNDC9 | P11T-E | Human | Esophagus | ESCC | 4.36e-14 | 8.11e-01 | 0.1426 |
| 10190 | TXNDC9 | P12T-E | Human | Esophagus | ESCC | 6.53e-33 | 6.05e-01 | 0.1122 |
| 10190 | TXNDC9 | P15T-E | Human | Esophagus | ESCC | 1.19e-28 | 6.50e-01 | 0.1149 |
| 10190 | TXNDC9 | P16T-E | Human | Esophagus | ESCC | 4.71e-22 | 4.38e-01 | 0.1153 |
| 10190 | TXNDC9 | P17T-E | Human | Esophagus | ESCC | 2.08e-07 | 6.60e-01 | 0.1278 |
| 10190 | TXNDC9 | P19T-E | Human | Esophagus | ESCC | 2.22e-07 | 1.11e+00 | 0.1662 |
| 10190 | TXNDC9 | P20T-E | Human | Esophagus | ESCC | 1.44e-25 | 6.34e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:000645719 | Oral cavity | LP | protein folding | 125/4623 | 212/18723 | 1.62e-26 | 8.45e-24 | 125 |
| GO:0006457111 | Skin | cSCC | protein folding | 131/4864 | 212/18723 | 2.96e-28 | 1.32e-25 | 131 |
| GO:0006457112 | Thyroid | PTC | protein folding | 137/5968 | 212/18723 | 8.29e-23 | 2.01e-20 | 137 |
| GO:000645733 | Thyroid | ATC | protein folding | 140/6293 | 212/18723 | 3.46e-22 | 8.09e-20 | 140 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TXNDC9 | SNV | Missense_Mutation | c.673N>C | p.Asp225His | p.D225H | O14530 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| TXNDC9 | SNV | Missense_Mutation | c.633N>T | p.Lys211Asn | p.K211N | O14530 | protein_coding | tolerated(0.07) | benign(0.067) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TXNDC9 | SNV | Missense_Mutation | novel | c.185N>T | p.Lys62Ile | p.K62I | O14530 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TXNDC9 | SNV | Missense_Mutation | c.633N>T | p.Lys211Asn | p.K211N | O14530 | protein_coding | tolerated(0.07) | benign(0.067) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TXNDC9 | SNV | Missense_Mutation | rs748796557 | c.221N>T | p.Arg74Ile | p.R74I | O14530 | protein_coding | tolerated(0.1) | benign(0.028) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TXNDC9 | SNV | Missense_Mutation | novel | c.241N>T | p.Asp81Tyr | p.D81Y | O14530 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| TXNDC9 | SNV | Missense_Mutation | c.528N>T | p.Glu176Asp | p.E176D | O14530 | protein_coding | deleterious(0.02) | probably_damaging(0.971) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TXNDC9 | SNV | Missense_Mutation | c.584N>T | p.Pro195Leu | p.P195L | O14530 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-55-8507-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TXNDC9 | SNV | Missense_Mutation | c.655N>C | p.Tyr219His | p.Y219H | O14530 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TXNDC9 | SNV | Missense_Mutation | novel | c.92C>G | p.Ser31Cys | p.S31C | O14530 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-97-A4M0-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |